{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:39:14Z","timestamp":1793313554595,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Higher Education Commission Pakistan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) is the most prevalent tumor in men, and Prostate-Specific Antigen (PSA) serves as the primary marker for diagnosis, recurrence, and disease-free status. PSA levels post-treatment guide physicians in gauging disease progression and tumor status (low or high). Clinical follow-up relies on monitoring PSA over time, forming the basis for dynamic prediction. Our study proposes a joint model of longitudinal PSA and time to tumor shrinkage, incorporating baseline variables. The research aims to assess tumor status post-treatment for dynamic prediction, utilizing joint assessment of PSA measurements and time to tumor status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We propose a joint model for longitudinal PSA and time to tumor shrinkage, taking into account baseline BMI and post-treatment factors, including external beam radiation therapy (EBRT), androgen deprivation therapy (ADT), prostatectomy, and various combinations of these interventions. The model employs a mixed-effect sub-model for longitudinal PSA and an event time sub-model for tumor shrinkage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Results emphasize the significance of baseline factors in understanding the relationship between PSA trajectories and tumor status. Patients with low tumor status consistently exhibit low PSA values, decreasing exponentially within one month post-treatment. The correlation between PSA levels and tumor shrinkage is evident, with the considered factors proving to be significant in both sub-models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared to other treatment options, ADT is the most effective in achieving a low tumor status, as evidenced by a decrease in PSA levels after months of treatment. Patients with an increased BMI were more likely to attain a low tumor status. The research enhances dynamic prediction for PCa patients, utilizing joint analysis of PSA and time to tumor shrinkage post-treatment. The developed model facilitates more effective and personalized decision-making in PCa care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-023-01374-8","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T10:03:04Z","timestamp":1701856984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Illustration of association between change in prostate-specific antigen (PSA) values and time to tumor status after treatment for prostate cancer patients: a joint modelling approach"],"prefix":"10.1186","volume":"23","author":[{"given":"Madiha","family":"Liaqat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"1374_CR1","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","DOI":"10.3322\/caac.21708"},{"key":"1374_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3390\/jcm8020201","volume":"8","author":"K Fujita","year":"2019","unstructured":"Fujita K, Hayashi T, Matsushita M, Uemura M, Nonomura N. Obesity, inflammation, and Prostate cancer. J Clin Med. 2019;8:201.","journal-title":"J Clin Med"},{"key":"1374_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year outcomes after monitoring, Surgery, or Radiotherapy for localized Prostate Cancer. N Engl J Med. 2016;375:1415\u201324.","journal-title":"N Engl J Med"},{"key":"1374_CR4","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S1470-2045(14)70328-6","volume":"15","author":"JW Denham","year":"2019","unstructured":"Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced Prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol. 2019;15:1076\u201389.","journal-title":"Lancet Oncol"},{"key":"1374_CR5","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591\u20137.","journal-title":"JAMA"},{"key":"1374_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1464-410X.2007.07138.x","volume":"101","author":"AR Rao","year":"2018","unstructured":"Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific antigen. BJU Int. 2018;101:5\u201310.","journal-title":"BJU Int"},{"key":"1374_CR7","doi-asserted-by":"crossref","unstructured":"Sheikh MT, Ibrahim JG, Gelfond JA, Sun W, Chen MH. Joint modelling of longitudinal and survival data in the presence of competing risks with applications to prostate cancer data. Stat Model. 201;21:72\u201394.","DOI":"10.1177\/1471082X20944620"},{"key":"1374_CR8","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1177\/0962280214535763","volume":"25","author":"M S\u00e8ne","year":"2016","unstructured":"S\u00e8ne M, Taylor JM, Dignam JJ, Jacqmin-Gadda H, Proust-Lima C. Individualized dynamic prediction of Prostate cancer recurrence with and without the initiation of a second treatment: development and validation. Stat Methods Med Res. 2016;25:2972\u201391.","journal-title":"Stat Methods Med Res"},{"key":"1374_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/ije\/dyu262","volume":"44","author":"\u00d6 Asar","year":"2015","unstructured":"Asar \u00d6, Ritchie J, Kalra PA, Diggle PJ. Joint modelling of repeated measurement and time-to-event data: an introductory tutorial. Int J Epidemiol. 2015;44:334\u201344.","journal-title":"Int J Epidemiol"},{"key":"1374_CR10","unstructured":"Rizopoulos D. The R package JMbayes for fitting joint models for longitudinal and time-to-event data using MCMC. arXiv Preprint arXiv. 2014;1404.7625."},{"key":"1374_CR11","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.0006-341X.2005.030929.x","volume":"61","author":"ER Brown","year":"2005","unstructured":"Brown ER, Ibrahim JG, DeGruttola V. A flexible B-spline model for multiple longitudinal biomarkers and survival. Biometrics. 2005;61:64\u201373.","journal-title":"Biometrics"},{"key":"1374_CR12","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/sim.4205","volume":"30","author":"D Rizopoulos","year":"2011","unstructured":"Rizopoulos D, Ghosh P. A bayesian semiparametric multivariate joint model for multiple longitudinal outcomes and time to event. Stat Med. 2011;30:1366\u201380.","journal-title":"Stat Med"},{"key":"1374_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/biostatistics\/kxp009","volume":"10","author":"C Proust-Lima","year":"2009","unstructured":"Proust-Lima C, Taylor JM. Development and validation of a dynamic prognostic tool for Prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach. Biostatistics. 2009;10:535\u201349.","journal-title":"Biostatistics"},{"key":"1374_CR14","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/ije\/dyab047","volume":"50","author":"ER Andrinopoulou","year":"2021","unstructured":"Andrinopoulou ER, Harhay MO, Ratcliffe SJ, Rizopoulos D. Reflection on modern methods: dynamic prediction using joint models of longitudinal and time-to-event data. Int J Epidemiol. 2021;50:1731\u201343.","journal-title":"Int J Epidemiol"},{"key":"1374_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.canlet.2015.12.022","volume":"380","author":"SL Shiao","year":"2016","unstructured":"Shiao SL, Chu GCY, Chung LW. Regulation of Prostate cancer progression by the Tumor microenvironment. Cancer Lett. 2016;380:340\u20138.","journal-title":"Cancer Lett"},{"key":"1374_CR16","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1177\/0962280218811837","volume":"28","author":"L Ferrer","year":"2019","unstructured":"Ferrer L, Putter H, Proust-Lima C. Individual dynamic predictions using landmarking and joint modelling: validation of estimators and robustness assessment. Stat Methods Med Res. 2019;28:3649\u201366.","journal-title":"Stat Methods Med Res"},{"key":"1374_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/biom.12562","volume":"73","author":"M Maziarz","year":"2017","unstructured":"Maziarz M, Heagerty P, Cai T, Zheng Y. On longitudinal prediction with time-to\u2010event outcome: comparison of modeling options. Biometrics. 2017;73:83\u201393.","journal-title":"Biometrics"},{"key":"1374_CR18","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1002\/sim.1392","volume":"21","author":"DK Pauler","year":"2002","unstructured":"Pauler DK, Finkelstein DM. Predicting time to Prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. Stat Med. 2002;21:3897\u2013911.","journal-title":"Stat Med"},{"key":"1374_CR19","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","volume":"65","author":"S Loeb","year":"2014","unstructured":"Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Etzioni R. Overdiagnosis and overtreatment of Prostate cancer. Eur Urol. 2014;65:1046\u201355.","journal-title":"Eur Urol"},{"key":"1374_CR20","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1200\/JCO.2005.12.156","volume":"23","author":"JM Taylor","year":"2005","unstructured":"Taylor JM, Yu M, Sandler HM. Individualized predictions of Disease progression following radiation therapy for Prostate cancer. J Clin Oncol. 2005;23:816\u201325.","journal-title":"J Clin Oncol"},{"key":"1374_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/biostatistics\/1.4.465","volume":"1","author":"R Henderson","year":"2000","unstructured":"Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics. 2000;1:465\u201380.","journal-title":"Biostatistics"},{"key":"1374_CR22","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2307\/2533118","volume":"53","author":"MS Wulfsohn","year":"1997","unstructured":"Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Biometrics. 1997;53:330\u20139.","journal-title":"Biometrics"},{"key":"1374_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: extending the Cox Model","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM. Modeling Survival Data: extending the Cox Model. Berlin: Springer; 2000."},{"key":"1374_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and Life-Tables. Journal of the Royal Statistical Society. Ser B (Methodological). 1972;34:187\u2013220.","journal-title":"Ser B (Methodological)"},{"key":"1374_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"1374_CR26","doi-asserted-by":"crossref","unstructured":"Fox J, Weisberg S. Cox proportional-hazards regression for survival data. An R and S-PLUS companion to applied regression; 2002.","DOI":"10.32614\/CRAN.package.car"},{"key":"1374_CR27","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1002\/sim.7027","volume":"35","author":"ER Andrinopoulou","year":"2016","unstructured":"Andrinopoulou ER, Rizopoulos D. Bayesian shrinkage approach for a joint model of longitudinal and survival outcomes assuming different association structures. Stat Med. 2016;35:4813\u201323.","journal-title":"Stat Med"},{"key":"1374_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2307\/2529876","volume":"38","author":"NM Laird","year":"1982","unstructured":"Laird NM, Ware JH. Random-effects models for Longitudinal Data. Biometrics. 1982;38:963\u201374.","journal-title":"Biometrics"},{"key":"1374_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2307\/271063","volume":"25","author":"AE Raftery","year":"1995","unstructured":"Raftery AE. Bayesian model selection in social research. Sociol Methodol. 1995;25:111\u201363.","journal-title":"Sociol Methodol"},{"key":"1374_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.2041-210x.2012.00261.x","volume":"4","author":"S Nakagawa","year":"2013","unstructured":"Nakagawa S, Schielzeth H. A general and simple method for obtaining R2 from generalized linear mixed-effects models. Methods Ecol Evol. 2013;4:133\u201342.","journal-title":"Methods Ecol Evol"},{"key":"1374_CR31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","volume":"69","author":"D Schoenfeld","year":"1982","unstructured":"Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69:239\u201341.","journal-title":"Biometrika"},{"key":"1374_CR32","doi-asserted-by":"publisher","DOI":"10.1201\/b11311","volume-title":"Dynamic prediction in clinical survival analysis","author":"H Van Houwelingen","year":"2011","unstructured":"Van Houwelingen H, Putter H. Dynamic prediction in clinical survival analysis. CRC Press; 2011."},{"key":"1374_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12874-022-01709-3","volume":"22","author":"H Parr","year":"2022","unstructured":"Parr H, Hall E, Porta N. Joint models for dynamic prediction in localised Prostate cancer: a literature review. BMC Med Res Methodol. 2022;22:245.","journal-title":"BMC Med Res Methodol"},{"key":"1374_CR34","first-page":"3658","volume":"14","author":"H Munir","year":"2022","unstructured":"Munir H, Ahmad F, Ullah S, Almutairi SM, Asghar S, Siddique T, Yaz H. Screening a novel six critical gene-based system of diagnostic and prognostic biomarkers in prostate adenocarcinoma patients with different clinical variables. Am J Translational Res. 2022;14:3658.","journal-title":"Am J Translational Res"},{"key":"1374_CR35","doi-asserted-by":"publisher","first-page":"103468","DOI":"10.1016\/j.ajp.2023.103468","volume":"81","author":"T Zhang","year":"2023","unstructured":"Zhang T, Tang X, Zhang Y, Xu L, Wei Y, Hu Y, et al. Multivariate Joint models for the dynamic prediction of psychosis in individuals with clinical high risk. Asian J Psychiatry. 2023;81:103468.","journal-title":"Asian J Psychiatry"},{"key":"1374_CR36","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.3390\/jcm11206102","volume":"11","author":"A Di Minno","year":"2022","unstructured":"Di Minno A, Aveta A, Gelzo M, Tripodi L, Pandolfo SD, Crocetto F, Imbimbo C, Castaldo G. 8-Hydroxy-2-Deoxyguanosine and 8-Iso-prostaglandin F2\u03b1: putative biomarkers to assess oxidative stress damage following robot-assisted radical prostatectomy (RARP). J Clin Med. 2022;11:6102.","journal-title":"J Clin Med"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-023-01374-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-023-01374-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-023-01374-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T04:00:41Z","timestamp":1730779241000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-023-01374-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1374"],"URL":"https:\/\/doi.org\/10.1186\/s12894-023-01374-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3171586\/v1","asserted-by":"object"}]},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"14 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is based on a retrospective analysis of secondary analysis of administrative data. Mayo Hospital informed patients that their collected data might be used for research purposes. Therefore, no informed consent to participate is needed as approved by the ethical committee of University of the Punjab. Personal information was kept confidential to others during data collection from reports. The study has been conducted in accordance with the Declaration of Helsinki. The study was approved by the College of Statistical and Actuarial Sciences Research Board and the ethical committee at the University of the Punjab, Lahore Pakistan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"202"}}